Table 1 Characteristics of Diagnostic Comparison Studies of 18F-FAMT and 18F-FDG
From: The diagnostic performance of 18F-FAMT PET and 18F-FDG PET for malignancy detection: a meta-analysis
Study (year) [Ref] | N | Mean/Median Age (range) | Sex (M/F) | Tumour & other pathology examined | No. of lesions | 18F-FAMT dose | 18F-FDG dose | PET studies interval | Follow-up period | Gold Standard & verification | Study design | Study Period | QUADAS Scoreb |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Inoue (1999) [6] | 20 | 41 ± 21 (1–71) | 8/12 | Brain tumour | 23 | 185 MBq | 200 MBq | Within 1 wk. | > 4 mo. | H (16), Img & Cln (4) | Pro | ND | 12 (6,11) |
Watanabe (2000) [12]a | 74 | 44 (12–83) | 37/38 | Musculoskeletal tumours: 24 bone, 48 soft tissue | 22 mlg, 53 bgn | 185–350 MBq | 185–350 MBq | ND | > 1 y. | H | Pro | 2/‘98–6/‘99 | 13 (11) |
Inoue (2001) [5]a | 19 | 58 (20–84) | 13/6 | Lung cancer (10), mlg myeloma (2), Chondrosarcoma (1), Prostate (1), mlg lymphoma (1), mlg of unknown origin (1), Schwannoma (1), Sarcoidosis (2) | 57 | 200–370 MBq | 200–370 MBq | Within 1 wk. | > 8 mo. | H (31), Img & Cln (26) | Pro | ND | 10 (1,6,7,11) |
Sato (2003) [13] | 14 | Gliomatosis: 45 (15–60) Non-neoplastic: 41.2 (23–76) | 4/4 5/1 | - Gliomatosis cerebri (8): Anaplastic (1), grade II astrocytoma (4) grade III astrocytoma (3) - Non-neoplastic diseases (6) | ND | 185 MBq | ND | 1–5 wk. (detailed) | ND | H (8) for gliomatosis Img & Cln for non-neoplasms | Pro | ND | 12 (6,11) |
Suzuki (2005) [11]a | 57 | 58.1 (27–87) | 29/28 | Fatty tissue tumour | 32 lipoma, 25 liposarcoma | 185–350 MBq | 185–350 MBq | ND | ND | H (57) | Pro | 9/‘97–12/‘03 | 12 (11,4Un) |
Kaira (2007) [7] | 41 | 61 (45–82) 43 (20–73) | 13/4 9/15 | Lung cancer (17) Sarcoidosis (24) | 9 AC, 6 SQC, 2 NSCLC, 16 LNM, 24 sarcoidosis | 4–5 MBq/kg | 5–6 MBq/kg | ND for lung cancer. Sarcoidosis: 1 wk. after diagnosis established. | > 2 y. | H (41) | Pro | Sarcoidosis: 9/‘98–8/‘05 | 12 (10,12) |
Miyakubo (2007) [9] a | 43 | ND (31–90) ND (32–81) | 16/20 5/2 | Maxillofacial tumours: mlg. (36), bgn. (7) and LNM (14) | 34 SQC, 1 rhabdomyosarcoma, 1 mucoepidermoid carcinoma, 14 LNM, 7 bgn | 5–6 MBq/kg | 5–6 MBq/kg | 2 wk. | > 6 mo. | H (43) | Pro | 5/‘99–7/‘06 | 13 (11) |
Kaira (2009) [24]a | 43 | 67 (41–79) | 33/10 | Thoracic tumours: mlg. (37), bgn. (6) | 19 AC, 9 SQC, 1 LCC, 2 atypical SQC, 3 Bronchoalveolar carci-noma, 1 carcinoid, 6 bgn | ND | 5 MBq/kg | 1–14 d. (mean: 4 d.) | ND | H (43) | Pro | 5/‘07–3/‘08 | 12 (11,12) |
Tian (2011) [23]a | 36 | ND (11–84) | 22/14 | Musculoskeletal tumour | 13 mlg, 23 bgn | 260 MBq | 320 MBq | Maximum 2 wk. | ND | H, Img & Cln (36) | Pro | ND | 13 (11) |